Iododiflunisal-betaAlaOMe: Salicylates look particularly interesting as drug candidates due to their long therapeutic tradition and wide clinical applications. Based on the diflunisal core structure, a salicylate drug with NSAID activity was selected for clinical trials against TTR amyloid diseases, and the authors designed around 40 iodinated derivatives; this one stood out due to the remarkable combined TTR binding vs. aggregation inhibition properties. Here, TTR is linked to amyloidosis.